. 2019 Feb 22;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115

Table 2. Associations Between Clinicopathological Parameters and Prognosis in Abiraterone.

Variable	Treatment Failure–Free Survival		Overall Survival
Variable	HR (95% CI)	P Value	HR (95% CI)	P Value
Age at pretreatment, HR (range), y	0.80 (0.24-2.76)	.72	2.09 (0.40-10.87)	.38
PSA at diagnosis, HR (range)	0.52 (0.047-2.54)	.47	0.33 (0.0017-4.57)	.50
Biopsy Gleason score
<8	1 [Reference]	NA	1 [Reference]	NA
≥8	1.14 (0.45-1.58)	.67	0.89 (0.45-1.99)	.77
PSA at pretreatment, HR (range)	9.88 (2.85-27.11)	.001^a	50.20 (12.26-191.36)	<.001^a
ECOG PS at pretreatment
0	1 [Reference]	NA	1 [Reference]	NA
1	1.48 (0.88-2.43)	.14	1.15 (0.60-2.14)	.67
≥2	1.89 (0.77-3.99)	.15	2.00 (0.78-4.48)	.14
Clinical M-stage
M0	0.87 (0.30-1.99)	.86	1.18 (0.19-3.97)	.83
M1a	0.79 (0.32-1.63)	.54	0.46 (0.075-1.55)	.24
M1b	1 [Reference]	NA	1 [Reference]	NA
M1c	2.23 (1.09-4.21)	.03^a	2.96 (1.24-6.29)	.02^a
Prior enzalutamide
Absence	1 [Reference]	NA	1 [Reference]	NA
Presence	3.51 (2.15-5.81)	<.001^a	2.23 (1.25-4.05)	.007^a
Prior docetaxel
Absence	1 [Reference]	NA	1 [Reference]	NA
Presence	1.87 (1.18-2.97)	.008^a	1.34 (0.75-2.40)	.32
HSD3B1 (rs1047303)
Homozygous wild type	1 [Reference]	NA	1 [Reference]	NA
Heterozygous variant type	0.32 (0.12-0.69)	.002^a	0.40 (0.13-0.94)	.04^a

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NA, not applicable; PS, performance status; PSA, prostate-specific antigen.

^{^a}

Statistically significant.